Insiders · NBP

NBP insider transactions

NovaBridge Biosciences (NBP) Form 4 insider transactions - real-time wire coverage of every officer, director, and 10% owner trade.

NBP insiders

Everyone who has filed a Form 3, 4, 5 or 144 at NovaBridge Biosciences, latest first. Follow anyone to get their next filing.

• Charles SilbersteinChief Financial Officer, since November 2026
• Phillip Andrew DennisChief Medical Officer, since March 2026-$11.4K
• Sean Wuxiong CaoChief Bus. Development Officer, since March 2026-$122K
• Martin William DewhurstDirector, since September 2026
• Cong Claire XuEVP, Clinical Development, since March 2026-$20.4K
• Robert A. LenzDirector, since March 2026
• Mark Arnold HaglerChief Commercial Officer, since April 2026+$577K
• Liwei Lorraine LinGeneral Counsel, since March 2026
• Srishti GuptaChief Executive Officer, Director, since July 2026
• Wei FuDirector, since March 2026
• Conor Chia-hung YangDirector, since March 2026
• Chu Denny Hsueh WenOfficer, since March 2026
• Xi-Yong FuOfficer, Director, since March 2026
• Xiaofan Neo ZhangChief Investment Officer, since March 2026
• Ming Kyler LeiChief Financial Officer, since March 2026
• Joanna Xuqiong WuOfficer, since March 2026
• Emmett CunninghamDirector, since March 2026
• Xin LiuDirector, since March 2026
• Adeline Yi ZhangGlobal Controller, since March 2026
• Ian Ying WooDirector, since March 2026
• Au Chun Kwok AlanDirector, since March 2026

Recent Form 3, 4, and 5 filings for NBP

• 6d
  SEC Form 3 filed by new insider Silberstein Charles

  3 - NovaBridge Biosciences (0001778016) (Issuer)
• 20d
  SEC Form 4 filed by NovaBridge Biosciences

  4 - NovaBridge Biosciences (0001778016) (Issuer)
• 48d
  Chief Medical Officer Dennis Phillip Andrew converted options into 23,695 units of Ordinary Shares and sold $5,828 worth of Ordinary Shares (8,209 units at $0.71), increasing direct ownership by 10% to 173,427 units (SEC Form 4)

  4 - NovaBridge Biosciences (0001778016) (Issuer)
• 58d
  Chief Bus. Development Officer Cao Sean Wuxiong sold $79,904 worth of Ordinary Shares (107,978 units at $0.74), decreasing direct ownership by 29% to 266,467 units (SEC Form 4) (for tax liability)

  4 - NovaBridge Biosciences (0001778016) (Issuer)
• 59d
  SEC Form 3 filed by new insider Dewhurst Martin William

  3 - NovaBridge Biosciences (0001778016) (Issuer)
• 61d
  Chief Bus. Development Officer Cao Sean Wuxiong converted options into 339,372 units of Ordinary Shares, increasing direct ownership by 968% to 374,445 units (SEC Form 4)

  4 - NovaBridge Biosciences (0001778016) (Issuer)
• 68d
  EVP, Clinical Development Xu Cong Claire converted options into 9,382 units of Ordinary Shares and sold $2,593 worth of Ordinary Shares (3,282 units at $0.79), increasing direct ownership by 2% to 304,201 units (SEC Form 4)

  4 - NovaBridge Biosciences (0001778016) (Issuer)
• 75d
  Director Lenz Robert A. converted options into 17,218 units of Ordinary Shares (SEC Form 4)

  4 - NovaBridge Biosciences (0001778016) (Issuer)
• 121d
  SEC Form 4 filed by Chief Commercial Officer Hagler Mark Arnold

  4 - NovaBridge Biosciences (0001778016) (Issuer)
• 121d
  SEC Form 4 filed by General Counsel Lin Liwei Lorraine

  4 - NovaBridge Biosciences (0001778016) (Issuer)
• 123d
  SEC Form 4 filed by Chief Executive Officer Gupta Srishti

  4 - NovaBridge Biosciences (0001778016) (Issuer)
• 123d
  SEC Form 3 filed by new insider Gupta Srishti

  3 - NovaBridge Biosciences (0001778016) (Issuer)
• 124d
  SVP, Clinical Development Xu Cong Claire converted options into 12,432 units of Ordinary Shares and sold $3,992 worth of Ordinary Shares (4,485 units at $0.89), increasing direct ownership by 3% to 298,101 units (SEC Form 4)

  4 - NovaBridge Biosciences (0001778016) (Issuer)
• 131d
  SEC Form 4 filed by Director Fu Wei

  4 - NovaBridge Biosciences (0001778016) (Issuer)
• 137d
  SEC Form 4 filed by Chief Bus. Development Officer Cao Sean Wuxiong

  4 - NovaBridge Biosciences (0001778016) (Issuer)
• 139d
  Chief Medical Officer Dennis Phillip Andrew converted options into 23,695 units of Ordinary Shares and sold $5,606 worth of Ordinary Shares (8,494 units at $0.66), increasing direct ownership by 11% to 157,941 units (SEC Form 4)

  4 - NovaBridge Biosciences (0001778016) (Issuer)
• 159d
  SVP, Clinical Development Xu Cong Claire converted options into 9,382 units of Ordinary Shares and sold $13,766 worth of Ordinary Shares (3,494 units at $3.94), increasing direct ownership by 2% to 290,154 units (SEC Form 4)

  4 - NovaBridge Biosciences (0001778016) (Issuer)
• 174d
  Officer Cao Sean Wuxiong sold $42,584 worth of Ordinary Shares (21,399 units at $1.99), decreasing direct ownership by 38% to 35,073 units (SEC Form 4) to cover taxes

  4 - NovaBridge Biosciences (0001778016) (Issuer)
• 194d
  Officer Hagler Mark Arnold bought $577,300 worth of Ordinary Shares (230,000 units at $2.51) (SEC Form 4)

  4 - NovaBridge Biosciences (0001778016) (Issuer)
• 200d
  SEC Form 3 filed by new insider Hagler Mark Arnold

  3 - NovaBridge Biosciences (0001778016) (Issuer)
• 212d
  Amendment: SEC Form 3 filed by new insider Xu Cong Claire

  3/A - NovaBridge Biosciences (0001778016) (Issuer)
• 222d
  SEC Form 3 filed by new insider Yang Conor Chia-Hung

  3 - NovaBridge Biosciences (0001778016) (Issuer)
• 229d
  SEC Form 3 filed by new insider Chu Denny Hsueh Wen

  3 - NovaBridge Biosciences (0001778016) (Issuer)
• 235d
  SEC Form 3 filed by new insider Dennis Phillip Andrew

  3 - NovaBridge Biosciences (0001778016) (Issuer)
• 235d
  SEC Form 3 filed by new insider Lin Liwei Lorraine

  3 - NovaBridge Biosciences (0001778016) (Issuer)
• 235d
  SEC Form 3 filed by new insider Fu Xi-Yong

  3 - NovaBridge Biosciences (0001778016) (Issuer)
• 235d
  SEC Form 3 filed by new insider Zhang Xiaofan Neo

  3 - NovaBridge Biosciences (0001778016) (Issuer)
• 235d
  SEC Form 3 filed by new insider Lei Ming Kyler

  3 - NovaBridge Biosciences (0001778016) (Issuer)
• 235d
  SEC Form 3 filed by new insider Wu Joanna Xuqiong

  3 - NovaBridge Biosciences (0001778016) (Issuer)
• 235d
  SEC Form 3 filed by new insider Fu Wei

  3 - NovaBridge Biosciences (0001778016) (Issuer)
• 235d
  SEC Form 3 filed by new insider Cao Sean Wuxiong

  3 - NovaBridge Biosciences (0001778016) (Issuer)
• 235d
  SEC Form 3 filed by new insider Cunningham Emmett

  3 - NovaBridge Biosciences (0001778016) (Issuer)
• 235d
  SEC Form 3 filed by new insider Xu Cong Claire

  3 - NovaBridge Biosciences (0001778016) (Issuer)
• 235d
  SEC Form 3 filed by new insider Liu Xin

  3 - NovaBridge Biosciences (0001778016) (Issuer)
• 235d
  SEC Form 3 filed by new insider Zhang Adeline Yi

  3 - NovaBridge Biosciences (0001778016) (Issuer)
• 235d
  SEC Form 3 filed by new insider Woo Ian Ying

  3 - NovaBridge Biosciences (0001778016) (Issuer)
• 235d
  SEC Form 3 filed by new insider Lenz Robert A.

  3 - NovaBridge Biosciences (0001778016) (Issuer)
• 235d
  SEC Form 3 filed by new insider Au Chun Kwok Alan

  3 - NovaBridge Biosciences (0001778016) (Issuer)